B-intervention	0	7	Neutron
O	8	14	versus
B-control	15	21	photon
I-control	22	34	radiotherapy
O	35	38	for
O	39	44	local
O	45	52	control
O	53	55	in
O	56	66	inoperable
O	67	73	breast
O	74	80	cancer
O	80	81	.

O	82	84	By
O	85	91	virtue
O	92	94	of
O	95	100	their
O	101	105	high
O	106	112	linear
O	113	119	energy
O	120	128	transfer
O	129	130	(
O	130	133	LET
O	133	134	)
O	135	150	characteristics
O	151	154	the
O	155	163	biologic
O	164	177	effectiveness
O	178	180	of
O	181	189	neutrons
O	190	192	is
O	193	197	less
O	198	207	dependent
O	208	210	on
O	211	217	tissue
O	218	229	oxygenation
O	230	237	tension
O	238	241	and
O	242	246	cell
O	247	252	cycle
O	253	258	phase
O	259	261	as
O	262	270	compared
O	271	273	to
O	274	278	that
O	279	283	with
O	284	291	photons
O	291	292	.

O	293	298	Hence
O	298	299	,
O	300	302	an
O	303	311	improved
O	312	320	clinical
O	321	328	benefit
O	329	331	is
O	332	334	to
O	335	337	be
O	338	346	expected
O	347	360	predominantly
O	361	363	in
O	364	369	large
O	369	370	,
O	371	378	hypoxic
O	379	382	and
O	383	389	slowly
O	390	397	growing
O	398	404	tumors
O	404	405	.

O	406	411	Since
O	412	413	a
O	414	419	short
O	420	426	course
O	427	429	of
O	430	442	radiotherapy
O	443	445	is
O	446	454	required
O	455	458	for
O	459	467	clinical
O	468	475	reasons
O	475	476	,
O	477	479	it
O	480	488	prompted
O	489	492	the
O	493	500	authors
O	501	503	to
O	504	512	initiate
O	513	514	a
O	515	523	randomly
O	524	534	controlled
O	535	540	trial
O	541	543	on
O	544	551	locally
O	552	560	advanced
O	561	567	breast
O	568	574	cancer
O	574	575	.

O	576	583	Between
O	584	588	1996
O	589	592	and
O	593	597	1999
O	597	598	,
B-total-participants	599	601	27
B-eligibility	602	610	patients
I-eligibility	611	615	with
I-eligibility	616	623	locally
I-eligibility	624	632	advanced
I-eligibility	633	639	breast
I-eligibility	640	646	cancer
O	647	651	were
O	652	662	irradiated
O	663	667	with
O	668	675	photons
O	676	677	(
O	677	679	60
O	680	682	Gy
O	682	683	,
O	684	686	30
O	687	696	fractions
O	696	697	;
O	698	699	8
O	700	702	MV
O	702	703	,
O	704	705	(
O	705	707	60
O	707	708	)
O	708	710	Co
O	710	711	)
O	712	714	or
O	715	723	neutrons
O	724	725	(
O	725	727	18
O	728	730	Gy
O	730	731	,
O	732	738	twelve
O	739	748	fractions
O	748	749	;
O	750	752	66
O	753	756	MeV
O	756	757	(
O	757	758	p
O	758	759	-
O	759	760	-
O	760	761	>
O	761	763	Be
O	763	764	)
O	764	765	)
O	765	766	.

O	767	770	The
O	771	775	mean
O	776	781	tumor
O	782	791	diameters
O	792	796	were
O	797	800	699
O	801	802	+
O	802	803	/
O	803	804	-
O	805	808	399
O	809	811	ml
O	812	815	for
O	816	819	the
O	820	826	photon
O	827	832	group
O	833	836	and
O	837	838	1
O	838	839	,
O	839	842	097
O	843	844	+
O	844	845	/
O	845	846	-
O	847	850	831
O	851	853	ml
O	854	856	in
O	857	860	the
O	861	868	neutron
O	869	874	group
O	874	875	.

O	876	881	After
O	882	883	a
O	884	888	mean
O	889	895	follow
O	895	896	-
O	896	898	up
O	899	905	period
O	906	908	of
O	909	911	21
O	911	912	.
O	912	913	5
O	914	920	months
O	921	926	tumor
O	927	937	involution
O	938	941	was
O	942	951	evaluated
O	952	954	in
B-total-participants	955	957	22
O	958	966	patients
O	966	967	.

B-outcome	968	975	Partial
I-outcome	976	979	and
I-outcome	980	988	complete
I-outcome	989	999	remissions
O	1000	1004	were
O	1005	1015	registered
O	1016	1018	in
B-iv-bin-abs	1019	1020	6
O	1020	1021	/
B-intervention-participants	1021	1023	10
O	1024	1032	patients
O	1033	1035	of
O	1036	1039	the
O	1040	1046	photon
O	1047	1052	group
O	1053	1056	and
B-cv-bin-abs	1057	1058	5
O	1058	1059	/
B-control-participants	1059	1061	12
O	1062	1070	patients
O	1071	1073	of
O	1074	1077	the
O	1078	1085	neutron
O	1086	1091	group
O	1091	1092	.

O	1093	1097	Late
B-outcome	1098	1103	grade
I-outcome	1104	1105	3
I-outcome	1105	1106	-
I-outcome	1106	1107	4
I-outcome	1108	1117	morbidity
O	1118	1127	according
O	1128	1130	to
O	1131	1135	RTOG
O	1136	1146	definition
O	1147	1150	was
O	1151	1157	scored
O	1158	1160	in
B-iv-bin-abs	1161	1162	5
O	1162	1163	/
B-intervention-participants	1163	1165	10
O	1166	1174	patients
O	1175	1177	in
O	1178	1181	the
O	1182	1188	photon
O	1189	1194	group
O	1195	1198	and
O	1199	1201	in
B-cv-bin-abs	1202	1203	6
O	1203	1204	/
B-control-participants	1204	1206	12
O	1207	1215	patients
O	1216	1218	in
O	1219	1222	the
O	1223	1230	neutron
O	1231	1236	group
O	1236	1237	.

O	1238	1242	With
O	1243	1249	regard
O	1250	1252	to
B-outcome	1253	1258	tumor
I-outcome	1259	1266	control
O	1267	1270	and
B-outcome	1271	1275	late
I-outcome	1276	1285	radiation
I-outcome	1286	1295	morbidity
O	1296	1298	no
O	1299	1310	differences
O	1311	1318	between
O	1319	1322	the
O	1323	1326	two
O	1327	1336	treatment
O	1337	1341	arms
O	1342	1346	were
O	1347	1355	observed
O	1355	1356	.

O	1357	1360	The
O	1361	1371	underlying
O	1372	1376	data
O	1377	1385	indicate
O	1386	1390	that
O	1391	1393	no
O	1394	1401	benefit
O	1402	1404	is
O	1405	1407	to
O	1408	1410	be
O	1411	1419	expected
O	1420	1424	from
O	1425	1432	neutron
O	1433	1440	therapy
O	1441	1443	in
O	1444	1450	breast
O	1451	1457	cancer
O	1457	1458	.
